Skip to main content

Resultados relacionados

Resultados totales (Incluyendo duplicados): 2
Encontrada(s) 1 página(s)

RIUMA. Repositorio Institucional de la Universidad de Málaga
Publication Artículo científico (JournalArticle)

West Nile virus unmasked: from gene variability to future challenges

  • Prieto-Vega, Samuel
  • Berzal Herranz, Alfredo
  • Garrido, Juan José
  • Arias, Armando
  • Grande-Pérez, Ana
  • Fernández-Escamilla, Ana María
  • Montoya, María
El virus del Nilo Occidental (WNV) es un ortoflavivirus transmitido por mosquitos cuyo ciclo de transmisión implica aves como reservorios y artrópodos vectores. Aunque no existen cifras globales exactas, estimaciones basadas en seroprevalencia indican entre 4 y 16 millones de infecciones al año. Con una mortalidad aproximada del 6–7% en los casos notificados, el WNV representa un desafío relevante para la salud pública. Esta revisión resume la biología molecular del WNV, abarcando la organización del genoma, la maduración proteica, los mecanismos de replicación y el papel de las regiones no traducidas y de las modificaciones postraduccionales en la adaptación viral. Se destaca la variabilidad genética intrahospedador y la naturaleza de cuasiespecie como elementos clave en la evasión inmunitaria y la evolución del virus. Asimismo, se analizan los factores ecológicos y epidemiológicos que influyen en su expansión, especialmente en el contexto del cambio climático y la alteración de la distribución de vectores. La revisión aborda también las manifestaciones clínicas, la patogénesis, los métodos diagnósticos y las estrategias terapéuticas actuales. Se describen enfoques emergentes de prevención y control, como la vigilancia entomológica, el desarrollo de vacunas y nuevos candidatos antivirales, incluidos péptidos dirigidos, anticuerpos y mutagénesis letal. El trabajo subraya la necesidad de sistemas de vigilancia integrados bajo el enfoque One Health y de acelerar el desarrollo de vacunas para reducir el riesgo de futuros brotes a nivel global., West Nile virus (WNV) is a mosquito-borne orthoflavivirus whose transmission cycle involves birds as reservoirs and arthropod vectors. Although precise global figures are lacking, seroprevalence-based estimates suggest between 4 and 16 million infections annually. With an approximate mortality of 6–7% among reported cases, WNV remains a significant public health challenge. This review summarizes the molecular biology of WNV, including genome organization, protein maturation, replication mechanisms, and the roles of untranslated regions and post-translational modifications in viral adaptation. Intrahost genetic variability and the quasispecies nature of WNV are highlighted as key factors in immune evasion and viral evolution. The review also examines ecological and epidemiological drivers of WNV spread, particularly in the context of climate change and shifting vector distributions. Clinical manifestations, pathogenesis, diagnostic methods, and current therapeutic strategies are discussed. Emerging approaches for prevention and control are addressed, including entomological surveillance, vaccine development, and novel antiviral candidates such as targeted peptides, antibodies, and lethal mutagenesis. The work underscores the need for integrated One Health surveillance systems and accelerated vaccine development to mitigate the risk of future global outbreaks., NextGenerationEU (Regulation EU 2020/2094), through CSIC’s Global Health Platform (PTI+ Salud Global), Spanish Ministry of Science, Spanish Ministry of Universities, Generalitat Valenciana, Ministerio de Ciencia, Innovación y Universidades and FEDER (EU), Junta de Comunidades de Castilla-La Mancha (JCCM), University of Castilla La Mancha (UCLM), Regional Government of Andalusia (Consejerıá de Universidad, Investigación e Innovación), Spain, CSIC Open Access Publication Support Initiative (PROA) through its Unit of Information Resources for Research (URICI)
RiuNet. Repositorio Institucional de la Universitat Politécnica de Valéncia
Publication Artículo científico (JournalArticle)

AG5 is a potent non-steroidal anti-inflammatory and immune regulator that preserves innate immunity

  • BOTELLA ASUNCION, PABLO|||0000-0003-2141-3069
  • Rivero-Buceta, Eva María
  • VIDAURRE-AGUT, CARLA
  • Lama, Raquel
  • Rey-Campos, Magalí
  • Moreno, Alejandro
  • Mendoza, Laura
  • Mingo-Casas, Patricia
  • Escribano-Romero, Estela
  • Gutiérrez-Adán, Alfonso
  • Saiz, Juan Carlos
  • Smerdou, Cristian
  • Gonzalez, Gloria
  • Prósper, Felipe
  • Argemí, Josepmaría
  • San Miguel, Jesus
  • Sánchez Cordón, Pedro J.
  • Figueras, Antonio
  • Quesada-Gómez, Jose Manuel
  • Novoa, Beatriz
  • Montoya, María
  • Martín-Acebes, Miguel A.
  • Pineda-Lucena, Antonio
  • Benlloch Babiera, José María
[EN] An archetypal anti-inflammatory compound against cytokine storm would inhibit it without suppressing the innate immune response. AG5, an anti-inflammatory compound, has been developed as synthetic derivative of andrographolide, which is highly absorbable and presents low toxicity. We found that the mechanism of action of AG5 is through the inhibition of caspase-1. Interestingly, we show with in vitro generated human monocyte derived dendritic cells that AG5 preserves innate immune response. AG5 minimizes inflammatory response in a mouse model of lipopolysaccharide (LPS)-induced lung injury and exhibits in vivo anti-inflammatory efficacy in the SARS-CoV-2-infected mouse model. AG5 opens up a new class of anti-inflammatories, since contrary to NSAIDs, AG5 is able to inhibit the cytokine storm, like dexamethasone, but, unlike corticosteroids, preserves adequately the innate immunity. This is critical at the early stages of any naïve infection, but particularly in SARS-CoV-2 infections. Furthermore, AG5 showed interesting antiviral activity against SARS-CoV-2 in humanized mice., This work has been supported by NextGenerationEU Recovery and Resilience Facility (RRF) through the PTI+ Global Health Platform of Spanish National Research Council, grants SGL2103023 (PBA), SGL2103053 (MMA) and SGL2103015 (MM); by Spanish National Research Council through the program Ayudas extraodinarias a proyectos de investigacion en el marco de las medidas urgentes extraodinarias para hacer frente al impacto economico ¿ y social del COVID19 , grants CSIC-COV19-093 (PBA) and CSIC-COV19-117 (MM); by Generalitat Valenciana through the program Ayudas urgentes para proyectos de investigacion, ¿ desarrollo tecnologico ¿ e innovacion ¿ (I+D+i) por la COVID-19 , grant GVA-COVID19/2021/059 (PBA); by the Conference of Rectors of the Spanish Universities, Spanish National Research Council and Banco Santander through the FONDO SUPERA COVID-19, grant CAPriCORn (JSM, JMB); by Severo Ochoa center of excellence program (grant CEX2021-001230-S) (PBA).